Adaptive Biotechnologies ADPT Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$20.02M+32.9% | -$13.58M+59.7% | $9.55M+130% | -$25.59M+44.7% | -$29.83M+37.2% | ||
| $3.42M-20.7% | $3.77M-6.3% | $3.98M-4.5% | $4.08M-10.9% | $4.31M-10.0% | ||
| $11.93M-1.8% | $12.72M-0.9% | $13.26M-2.0% | $13.36M+3.1% | $12.15M-15.0% | ||
| -$2.05M-210% | $5.54M+517% | $536K-89.7% | $702K+111% | $1.86M-54.0% | ||
| $1.32M+598% | $10K+100% | $1.35M+179% | -$95K— | -$264K+76.2% | ||
| -$7.51M+22.3% | $1.17M-72.7% | —— | —— | -$9.67M-145% | ||
| $824K+269% | —— | $2.52M+80.4% | $497K— | -$489K+67.8% | ||
| $98K+1,533% | -$137K-2,640% | $0+100% | -$11K+47.6% | $6K+200% | ||
| $4M+220% | $0+100% | -$32.79M-410% | -$4.29M— | -$3.33M-39.0% | ||
| $419K0.0% | $429K+0.2% | $428K0.0% | $423K-0.2% | $419K-0.9% | ||
| -$9.54M+66.5% | $0+100% | -$7.13M+73.7% | -$12.43M+28.2% | -$28.48M+25.7% | ||
| $796K-36.8% | $636K+695% | $409K+18.9% | $655K-62.1% | $1.26M-16.7% | ||
| $9.14M-64.2% | —— | $17.28M+227% | $3.35M-43.1% | $25.57M-42.5% | ||
| $5.03M-7.8% | $9.13M+7,092% | $1.68M+4,110% | $1.61M+5,267% | $5.45M+12,289% | ||
| $7.5M+37.6% | $21.66M+16,954% | $1.68M+4,110% | $1.61M+5,267% | $5.45M+12,289% | ||
| $7.11M+180% | $15.46M— | $11.84M+154% | -$7.47M+34.4% | $2.54M-59.0% | ||
| $3.58M+51.0% | $4.7M+102% | $2.94M+36.4% | $2.62M+25.2% | $2.37M+3.7% | ||
| $136K-85.8% | $288K-80.2% | $516K-74.3% | $750K-64.3% | $958K-63.8% | ||
| $419K0.0% | $429K+0.2% | $428K0.0% | $423K-0.2% | $419K-0.9% | ||
| $3.42M-20.7% | $3.77M-6.3% | $3.98M-4.5% | $4.08M-10.9% | $4.31M-10.0% | ||
| $347K— | $0— | —— | —— | $0— | ||
| -$2.6M-27.8% | -$2.66M+10.5% | -$2.57M-57.2% | -$3.2M-42.9% | -$2.04M+20.2% | ||
| $824K+269% | —— | $2.52M+80.4% | $497K— | -$489K+67.8% | ||
| -$10K+90.1% | —— | —— | —— | -$101K-121% | ||
| $1.45M+10.5% | $1.37M+6.2% | $1.35M+6.0% | $1.33M-0.9% | $1.31M-4.2% | ||
| -$14K+81.6% | -$101K— | -$434K— | $0+100% | -$76K+33.3% | ||
| $655K+331% | —— | —— | —— | -$283K+56.8% | ||
| $2.48M— | —— | —— | —— | $0— | ||
| $159K-24.6% | —— | $444K— | $13K— | $211K-81.1% | ||
| -$10.33M+65.3% | $0+100% | -$7.54M+72.5% | -$13.09M+31.2% | -$29.74M+25.4% | ||
| -$10.33M+65.3% | $0+100% | -$7.54M+72.5% | -$13.09M+31.2% | -$29.74M+25.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Adaptive Biotechnologies generate?
- Adaptive Biotechnologies (ADPT) generated -$29.1M in operating cash flow over the trailing twelve months.
- What is Adaptive Biotechnologies's free cash flow?
- After $2.5M of capital expenditures, Adaptive Biotechnologies's free cash flow was -$31.0M over the trailing twelve months, up 65.1% year over year.
- Where does Adaptive Biotechnologies's cash flow data come from?
- Every line is extracted from Adaptive Biotechnologies's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
